Table 2 Possibly treatment-related adverse events in the mITT population according to CTCAE v5

Diarrhea (grade I–II)

6 (18.8%)

–

Abdominal cramps (grade I–II)

2 (6.3%)

–

Nausea (grade I–II)

1 (3.1%)

–

Fever (grade I–II)

1 (3.1%)

–

Dysgeusia (grade I–II)

1 (3.1%)

–

Syncope (grade III)

–

1 (3.2%)

Hypertension (grade I–II)

–

2 (6.5%)

QTc prolongation (grade I–II)

7 (21.9%)

7 (22.6%)